Last reviewed · How we verify
NCT06461936
Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCC
trial testing Sintilimab in HCC in 620 participants. Participants enrolled and being followed up; not accepting new ones.
30 April 2024
Quick facts
| Lead sponsor | Chen Xiaoping |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 620 |
| Start date | 1 January 2019 |
| Primary completion | 30 April 2024 |
| Estimated completion | 30 April 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Sintilimab — full drug profile →
- Lenvatinib (LENVATINIB) — full drug profile →
Conditions studied
- HCC — all drugs for HCC →
- Adjuvant Therapy — all drugs for Adjuvant Therapy →
- Immunotherapy — all drugs for Immunotherapy →
- Recurrence — all drugs for Recurrence →
Sponsor
Chen Xiaoping — full company profile →
Who can join
Adults 18 to 75, any sex, with HCC or Adjuvant Therapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC positive patients have a higher rate of postoperative recurrence. However, it is not clear how the surgical prognosis of VETC-positive patients can be improved.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06461936
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sintilimab
Trials testing the same drug.
- NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
- NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
- NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
- NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
- NCT07515625 — Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesop · Phase 2 · not yet recruiting
Other recruiting trials for HCC
Currently open trials in the same condition.
- NCT07145801 — Y-90 Treatment Response Using Transarterial Radioembolization · Phase 2 · recruiting
- NCT07300488 — Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma · Phase 2, PHASE3 · active not recruiting
- NCT07334483 — A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC · Phase 2 · recruiting
- NCT07099274 — Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy f · Phase 2 · recruiting
- NCT06717919 — HOPE Against Cancer Recurrence in HCC · Phase 4 · recruiting
Other Chen Xiaoping trials
Trials by the same sponsor.
- NCT06463444 — Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models · Phase 1 · recruiting
- NCT06420440 — Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model · Phase 2 · recruiting
- NCT06311916 — Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model. · Phase 4 · not yet recruiting
- NCT06311942 — Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC. · Phase 4 · recruiting
- NCT06311929 — Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06461936 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chen Xiaoping
- Last refreshed: 17 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06461936.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing